

# Metabolic phenotype of clinical and environmental *Mycobacterium avium* subsp. *hominissuis* isolates

Andrea Sanchini<sup>1</sup>, Flavia Dematheis<sup>2</sup>, Torsten Semmler<sup>3</sup>, Astrid Lewin<sup>Corresp. 1</sup>

<sup>1</sup> Division 16, Mycotic and Parasitic Agents and Mycobacteria, Robert Koch Institute, Berlin, Germany

<sup>2</sup> Institute of Microbiology and Epizootics, Free University Berlin, Berlin, Germany

<sup>3</sup> NG 1 Microbial Genomics, Robert Koch Institute, Berlin, Germany

Corresponding Author: Astrid Lewin

Email address: LewinA@rki.de

**Background.** *Mycobacterium avium* subsp. *hominissuis* (MAH) is an emerging opportunistic human pathogen. It can cause pulmonary infections, lymphadenitis and disseminated infections in immunocompromised patients. In addition, MAH is widespread in the environment, since it has been isolated from water, soil or dust. In the recent years, knowledge on MAH at molecular level substantially increased. On the contrary, knowledge of the MAH metabolic phenotypes remains limited.

**Methods.** In this study for the first time we analyzed the metabolic substrate utilization of ten MAH isolates, five from clinical and five from environmental source. We used the BIOLOG Phenotype Microarray™ technology. This technology permits the rapid and global analysis of metabolic phenotypes.

**Results.** The ten MAH isolates tested showed different metabolic patterns pointing to high intra-species diversity. Our MAH isolates preferred to use fatty acids such as Tween, caproic, butyric and propionic acid as a carbon source, and L-cysteine as a nitrogen source. Environmental MAH isolates resulted to be more metabolically active than clinical isolates, since the former metabolized more strongly butyric acid ( $p = 0.0209$ ) and propionic acid ( $p = 0.00307$ ).

**Discussion.** Our study provides new insight into the metabolism of MAH. Understanding how bacteria utilize substrates during infection might help the developing of strategies to fight such infections.

1 **Article Title**

2 Metabolic phenotype of clinical and environmental *Mycobacterium avium* subsp. *hominissuis*

3 isolates

4

5 **Authors**

6 Andrea Sanchini<sup>1</sup>, Flavia Dematheis<sup>2</sup>, Torsten Semmler<sup>3</sup>, Astrid Lewin<sup>1,\*</sup>

7

8 **Author affiliations**

9 <sup>1</sup> Division 16, Mycotic and Parasitic Agents and Mycobacteria, Robert Koch Institute, Berlin,

10 Germany

11 <sup>2</sup> Institute of Microbiology and Epizootics, Free University Berlin, Berlin, Germany

12 <sup>3</sup> NG 1 Microbial Genomics, Robert Koch Institute, Berlin, Germany

13

14 **Corresponding author**

15 Dr Astrid Lewin

16 Division 16, Mycotic and Parasitic Agents and Mycobacteria, Robert Koch Institute, Seestraße

17 10, 13353, Berlin, Germany.

18 Telephone: +4930187542112

19 E-mail: [LewinA@rki.de](mailto:LewinA@rki.de)

20

## 21 **Abstract**

22 **Background.** *Mycobacterium avium* subsp. *hominissuis* (MAH) is an emerging opportunistic  
23 human pathogen. It can cause pulmonary infections, lymphadenitis and disseminated infections  
24 in immuno-compromised patients. In addition, MAH is widespread in the environment, since it  
25 has been isolated from water, soil or dust. In the recent years, knowledge on MAH at molecular  
26 level substantially increased. On the contrary, knowledge of the MAH metabolic phenotypes  
27 remains limited.

28 **Methods.** In this study for the first time we analyzed the metabolic substrate utilization of ten  
29 MAH isolates, five from clinical and five from environmental source. We used the BIOLOG  
30 Phenotype Microarray™ technology. This technology permits the rapid and global analysis of  
31 metabolic phenotypes.

32 **Results.** The ten MAH isolates tested showed different metabolic patterns pointing to high intra-  
33 species diversity. Our MAH isolates preferred to use fatty acids such as Tween, caproic, butyric  
34 and propionic acid as a carbon source, and L-cysteine as a nitrogen source. Environmental MAH  
35 isolates resulted to be more metabolically active than clinical isolates, since the former  
36 metabolized more strongly butyric acid ( $p = 0.0209$ ) and propionic acid ( $p = 0.00307$ ).

37 **Discussion.** Our study provides new insight into the metabolism of MAH. Understanding how  
38 bacteria utilize substrates during infection might help the developing of strategies to fight such  
39 infections.

40

41

## 42 Introduction

43 *Mycobacterium avium* subsp. *hominissuis* (MAH) is clinically one of the most relevant non-  
44 tuberculous mycobacteria (Tortoli 2014). MAH is an opportunistic human pathogen causing  
45 pulmonary infections, lymphadenitis in small children and disseminated infections (Despierres et  
46 al. 2012; Rindi & Garzelli 2014). It is of increasing public health relevance, with reports of  
47 MAH infections increasing worldwide (Hoefsloot et al. 2013). Moreover, MAH is widespread in  
48 the environment (Falkinham 2013; Lahiri et al. 2014). In recent years, there have been  
49 substantial advances in the analysis of bacteria at the molecular level. Indeed, several whole  
50 genome sequences are now available for many mycobacterial species, including MAH  
51 (Bannantine et al. 2014; Kim et al. 2012; Uchiya et al. 2013; Wynne et al. 2010). In contrast,  
52 there has been little concomitant advance in knowledge at the phenotypic level. Phenotype  
53 analysis deserves greater attention, as it is the phenotype that selection pressure acts upon to  
54 confer evolutionary advantages to the bacterial species (Plata et al. 2015). In order to address this  
55 knowledge gap for bacterial phenotypes, BIOLOG Inc. developed the Phenotype MicroArray™  
56 (PM) (BIOLOG, Hayward CA), a high throughput method for the rapid and global analysis of  
57 microbial metabolic phenotypes (Bochner 2003; Bochner 2009; Bochner et al. 2001; Bochner et  
58 al. 2008). The PM technology consists of several commercially available 96-well plates in which  
59 every well has a different substrate, allowing nearly 2000 different microbial metabolic  
60 phenotypes to be tested (Bochner 2003; Bochner 2009; Bochner et al. 2001; Bochner et al.  
61 2008). PM technology has been applied to several microorganisms, including mycobacteria  
62 (Baloni et al. 2014; Bochner et al. 2008; Borglin et al. 2012; Chen et al. 2012; Gupta et al. 2015;  
63 Johnson et al. 2008; Khatri et al. 2013; Lofthouse et al. 2013; Mackie et al. 2014; Mishra &  
64 Daniels 2013; Nai et al. 2013; Omsland et al. 2009; Tohsato & Mori 2008). One possible

65 application of PM is the detection of phenotype changes due to gene knock-out. For example,  
66 Chen and co-authors showed that a *leuD* mutant of *M. avium* subsp *paratuberculosis* lost the  
67 ability to use several carbon, nitrogen, sulfur and phosphorous substrates (Chen et al. 2012).  
68 Other researchers showed that the use of 12 carbon substrates differentiated *M. tuberculosis* from  
69 *M. bovis* (Khatri et al. 2013; Lofthouse et al. 2013).

70 To date, there have been no reports of PM data for the emerging human pathogen MAH. In this  
71 study we tested clinical and environmental isolates of MAH using the PM technology. Our aim  
72 was to investigate if the PM technology was applicable to MAH isolates, to describe the  
73 metabolic substrates utilized by MAH isolates and to identify any metabolic differences between  
74 clinical and environmental MAH isolates.

## 76 **Materials and Methods**

### 77 **Bacterial isolates and BIOLOG phenotype microarray**

78 We analyzed five clinical and five environmental MAH isolates (Table 1).

79 We performed the BIOLOG Phenotype Microarray™ (BIOLOG, Hayward, CA) according to  
80 the manufacturer's recommendations. The technology is based on the measurement of bacterial  
81 respiration, which produces NADH (Bochner et al. 2001). If bacteria are able to metabolize a  
82 specific substrate, electrons from NADH reduce a tetrazolium dye in an irreversible reaction  
83 generating a purple color in the PM plate wells. This color change is measured and recorded  
84 every 15 minutes by the reporter instrument OmniLog™ (BIOLOG, Hayward, CA), generating a  
85 kinetic response curve for each well (Bochner 2003; Bochner 2009).

86 The ten MAH isolates were tested with the 96-wells plates PM1 to PM4, containing 190 carbon  
87 (PM1 and PM2), 95 nitrogen (PM3), 59 phosphorous (PM4) and 35 sulfur (PM4) substrates. The  
88 PM plates 1, 2 and 3 include one negative control well, in which bacteria are tested without any  
89 substrate. The PM4 plate includes two negative control wells, one for the phosphorus and one for  
90 the sulfur substrates. All isolates were tested three times. Briefly, we cultivated each MAH  
91 isolate in 30 ml of 7H10 Middlebrook medium supplemented with 10% modified ADC-  
92 enrichment (2% of glucose, 5% of BSA, 0,85% of NaCl) until an OD<sub>600 nm</sub> of 0.3-0.6 was  
93 achieved (mid-logarithmic phase of growth). The use of liquid cultures in place of agar reduces  
94 bacterial clumping. Bacterial cultures were harvested by centrifugation for 10 minutes at 4000g  
95 and pellets were re-suspended in 10 ml of distilled water. Bacterial cells were starved for one  
96 night in water at room temperature to minimize false positive reactions due to nutrient  
97 accumulation in MAH cells and to ensure the use of the substrates provided by the PM plates.

98 The following day the cells were centrifuged and re-suspended using a sterile stick in tubes  
99 containing 10 ml of GN/GP-IF-0a (BIOLOG inoculating fluid), 120  $\mu$ l of 100 $\times$  BIOLOG Redox  
100 Dye Mix G and 1 ml of the appropriate additive (Table 2), until 85% transmittance was reached  
101 as measured using the turbidimeter provided by BIOLOG. In order to reduce bacterial clumping,  
102 the sterile stick used for inoculation was ground against the wall of the tube. A volume of 100  $\mu$ l  
103 of this final suspension was added to each of the 96 wells of the PM plates. The PM plates were  
104 then sealed to avoid drying and incubated at 37°C in the OmniLog® (BIOLOG, Hayward, CA)  
105 incubator reader for 8 days.

106 As recommended by BIOLOG, we tested plates PM1 to PM4 using the same assay protocol but  
107 without addition of bacteria in order to identify wells with abiotic dye reduction, which can  
108 generate false positive results.

#### 109 **Analysis of BIOLOG phenotype microarray data**

110 The raw kinetic data were exported as CSV files using OmniLog PM file Management/kinetic  
111 Analysis module (Bochner 2003; Khatri et al. 2013). Differences in the metabolization of the  
112 different substrates by the ten MAH isolates were investigated by analyzing the maximum height  
113 of the bacterial respiration curves (parameter A) using the R-package opm (Vaas et al. 2013). To  
114 allow comparisons across plates processed in different experimental runs, the A parameters were  
115 normalized by subtracting the well mean of the negative control (Vaas et al. 2013). Furthermore,  
116 the A parameters of the triplicates were combined by calculating the mean and discretized into  
117 “positive”, “moderate” and “negative” metabolization using the method “discrete” within the R-  
118 opm package. Substrates differentiating the isolates from each other were visualized as a  
119 heatmap generated using the R-packages heatmap.plus with the Euclidean algorithm. The

120 heatmap displays the utilization of each substrate with a color key: yellow for strong positive  
121 metabolization, green for moderate metabolization and blue for no metabolization.

## 122 **Analysis of metabolic pathways**

123 The metabolic pathways of butyric and propionic acids were identified from the KEGG pathway  
124 database of the reference strain *M. avium* 104 (Kanehisa et al. 2016). All genes of the pathways  
125 were screened in the genomes of the ten MAH using Geneious version 8 (Kearse et al. 2012).

## 126 **Statistical analyses**

127 We generated two groups, one with data from all clinical isolates and the other with data from all  
128 environmental isolates. Statistical differences between clinical and environmental isolates in the  
129 metabolization of butyric acid and propionic acid were evaluated by means of 95% family-wise  
130 comparison of group means (Tukey contrast test) of the parameter A on specific wells using the  
131 function “opm\_mcp” within the opm R-package. A p value less than 0.05 was considered to be  
132 statistically significant.

## 133 **Whole genome sequencing of MAH isolates**

134 Genomic DNAs were extracted from the MAH isolates as described previously (Lewin et al.  
135 2003). Whole genome sequencing (WGS) was performed using Illumina MiSeq 300 bp paired-  
136 end sequencing, yielding a coverage that exceeded 100x. The NGS QC tool kit was used to  
137 assess the quality of the data reads, which was set as reads with a minimum of 70 % of bases  
138 having a phred score greater than 20 (Patel & Jain 2012). De novo assembly of the resulting  
139 reads into multiple contigs was performed using CLC Genomics Workbench 8.0 (CLC bio,  
140 Aarhus, Denmark) and contigs annotation was done using RAST (Aziz et al. 2008).

**141 Determination of the maximum common genome and clustering analysis**

142 We determined the maximum common genome (MCG), comprising those genes present in all of  
143 the ten MAH genomes, as reported previously (von Mentzer et al. 2014). All these genes were  
144 then extracted from all genomes, concatenated and aligned. The resulting alignment was used to  
145 generate a clustering tree using RAxML 8.1 (Stamatakis 2014).

## 146 Results

### 147 Substrate utilization of the ten MAH isolates

148 We tested the capability of our ten MAH isolates to metabolize 379 different substrates. In total,  
149 334/379 (88.1 %) substrates were negative for all of the isolates (see Supplemental Table S1). A  
150 total of 23/379 (6.1 %) substrates caused abiotic reactions and were excluded from further  
151 analysis. A list of false-positive substrates is shown in the Supplemental Table S2. The kinetic  
152 curves corresponding to the control plates PM1 to PM4 tested without bacteria are presented in  
153 the Supplemental Fig. S1

154 Only two carbon substrates, the fatty acid derivatives Tween 20 and Tween 40 were strongly  
155 positive for all of the ten MAH isolates. The kinetic curves for these substrates reached 250  
156 Omnilog units, amongst the highest values recorded in our analysis (see Supplemental Fig. S2  
157 for all kinetic curves of the ten MAH isolates). The opm analysis revealed that a total of 20/379  
158 (5.3 %) substrates were metabolized differently among the MAH isolates (Table 3). We therefore  
159 carried out further analysis using only these substrates. The majority of these 20 substrates were  
160 carbon substrates, 15/20 (75.0 %), followed by 3 nitrogen and 2 phosphorous substrates. The  
161 heatmap in Fig. 1 shows the utilization of these 20 substrates among the ten MAH isolates. The  
162 isolates are grouped according to their substrate utilization. Isolates utilizing similar substrates  
163 appear to cluster together.

164 Two major clusters, each composed of five isolates, could be observed. One was rich in  
165 environmental isolates (4/5) and the other was rich in clinical isolates (4/5). The substrates  
166 predominantly contributing to this clustering were butyric acid and propionic acid and indeed,

167 the Tukey's test revealed that environmental isolates metabolized more strongly butyric acid ( $p =$   
168 0.0209) and propionic acid ( $p = 0.00307$ ) than clinical isolates with statistical significance.

169 Regarding the analysis of the metabolic pathways of these two substrates, in the reference strain  
170 MAH 104, 147 genes are known to be involved in the butyric acid and propionic acid pathways  
171 (Kanehisa et al. 2016). Based the WGS of the ten isolates we analysed the distribution of these  
172 genes in our ten isolates. However, no difference was observed in gene distribution among  
173 clinical and environmental MAH isolates (data not shown), pointing to differences in gene  
174 regulation and not in gene content.

#### 175 **Clustering analysis by whole genome sequencing**

176 The WGS of the two reference strains MAH 104 and MAH TH135 were already in the GenBank  
177 database and we submitted the remaining genomes at DDBJ/EMBL/GenBank under the  
178 BioProject Number PRJNA299461. The MCG, the maximum number of genes shared by all ten  
179 MAH isolates was 1,658, the alignment of which spanned 1.378 Mbp. The clustering analysis of  
180 the ten MAH isolates is shown in Fig. 2. By comparing the genetic clustering obtained by WGS  
181 with the phenotypic clustering obtained through BIOLOG PM we observed slight differences.  
182 For examples, the isolates MAH E-96-2 and MAH E-82-7, which share identical metabolic  
183 profiles, were genetically more distant from each other. Interestingly, at the genetic level there  
184 was no obvious clustering between the group of clinical and the group of environmental isolates.

185

**186 Discussion**

187 This study represents the first phenotypic analysis of a collection of clinical and environmental  
188 MAH isolates using the Biolog PM technology. We showed that the PM technology works well  
189 and can be performed with MAH isolates. Strong positive reactions with several substrates were  
190 observed with kinetic curves exceeding 200 Omnilog dye units. Although some substrates were  
191 metabolized only moderately by our MAH isolates (green in Fig. 1), this might be due to the fact  
192 that the use of such substrates by bacteria has a time lag.

193 The ten MAH isolates showed different metabolic patterns pointing to high intra-species  
194 diversity. Only two out of the ten isolates had identical heatmap profiles (MAH E-96-2 and  
195 MAH E-82-7).

196 Our study showed that MAH isolates prefer to metabolize fatty acids as a carbon source. Indeed,  
197 the Tween substrates were strongly metabolized by all MAH isolates tested. This is in agreement  
198 with prior studies, showing that Tween substrates were widely used by different mycobacterial  
199 species (Baloni et al. 2014; Chen et al. 2012; Hayashi et al. 2010; Khatri et al. 2013; Lofthouse et  
200 al. 2013; Wang et al. 2011). It has been reported that mycobacteria hydrolyze Tween 80 to  
201 generate the fatty acid oleic acid, which can enter the Tricarboxylic acid (TCA) cycle or can be  
202 used as a substrate for energy production (Lofthouse et al. 2013; Vandal et al. 2009). Other fatty  
203 acids used by the majority of our MAH isolates are represented by two short fatty acids, caproic  
204 acid and butyric acid (Kanehisa & Goto 2000; Kanehisa et al. 2016; Khatri et al. 2013). Caproic  
205 acid and its derivatives are involved in several mycobacterial pathways such as the degradation  
206 of aromatic compounds, oxocarboxylic acid metabolism or lysine degradation (Kanehisa & Goto  
207 2000; Kanehisa et al. 2016). The butyric acid is the final product of butanoate metabolism.

208 Propionic acid is another fatty acid used by our MAH isolates and this represents the terminal  
209 product of propanoate metabolism (Kanehisa & Goto 2000; Kanehisa et al. 2016). The nitrogen  
210 source L-cysteine, used by six of our MAH isolates, is the final product of cysteine metabolism  
211 and is involved in the biosynthesis of other amino acids such as methionine and histidine (Baloni  
212 et al. 2014; Kanehisa & Goto 2000; Kanehisa et al. 2016).

213 The question of whether bacteria of the same species originating from either clinical or  
214 environmental sources differ from each other is still a matter of discussion. Li and co-authors  
215 showed that comparative genome analysis clearly distinguished clinical and environmental  
216 *Vibrio parahaemolyticus* isolates from each other (Li et al. 2014). In contrast, other researchers  
217 have reported no difference between clinical and environmental *Pseudomonas aeruginosa*  
218 isolates with regard to virulence and metabolic properties (Alonso et al. 1999; Vives-Florez &  
219 Garnica 2006). Although our study did not reveal any clear distinction between clinical or  
220 environmental MAH isolates at the level of the whole genome, we observed differences between  
221 clinical and environmental isolates with regard to substrate utilization. The most intriguing  
222 difference is that the two fatty acids butyric acid and propionic acid are metabolized more by the  
223 environmental than by clinical isolates. Such a higher metabolic activity might be advantageous  
224 for survival in an environment presenting a wider range of nutritional conditions than the host  
225 cells alone. Further studies testing a larger number of isolates from different origins might clarify  
226 this. In addition, it has been showed that in bacteria the fatty acids have a role in adaptation to  
227 different environmental conditions (de Sarrau et al. 2012; de Sarrau et al. 2013; Diomande et al.  
228 2015).

**229 Conclusions**

230 Our study contributes to the understanding of the emerging pathogen MAH at the phenotypic and  
231 metabolic level. Understanding how bacteria utilize their own or host-derived substrates during  
232 infection might help the development of strategies to fight such infections. We encourage  
233 phenotypic testing of microbial isolates from different ecological niches to identify key  
234 substrates or pathways that can be used as targets for drug development or for selective growth  
235 media development.

236

**237 Acknowledgments**

238 We would like to thank Barry Bochner (President of BIOLOG) for his invaluable input to this  
239 study and Brian Weinrick (Albert Einstein College of Medicine, New York City) for his support  
240 in developing the BIOLOG laboratory protocol. Elvira Richter (National Reference Center for  
241 Mycobacteria, Borstel, Germany) and Roland Schulze-Röbbecke (University Hospital  
242 Düsseldorf) provided a number of MAH isolates, Carsten Schwarz (Christiane Herzog Zentrum,  
243 Charité, Berlin) provided respiratory samples from cystic fibrosis patients and Kei-ichi Uchiya  
244 provided the reference strain MAH TH135. We thank Katharina Schaufler (Free University  
245 Berlin) for her support with the BIOLOG data analysis and Inga Eichorn (Free University Berlin)  
246 for her help with the whole genome sequencing data. We thank Steve Norley (Robert Koch  
247 Institute, Berlin) for the English revision of the manuscript.

248

249

250 **References**

- 251 Alonso A, Rojo F, and Martinez JL. 1999. Environmental and clinical isolates of *Pseudomonas*  
252 *aeruginosa* show pathogenic and biodegradative properties irrespective of their origin.  
253 *Environ Microbiol* 1:421-430.
- 254 Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass  
255 EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK,  
256 Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O,  
257 Vonstein V, Wilke A, and Zagnitko O. 2008. The RAST Server: rapid annotations using  
258 subsystems technology. *BMC Genomics* 9:75. 10.1186/1471-2164-9-75
- 259 Baloni P, Padiadpu J, Singh A, Gupta KR, and Chandra N. 2014. Identifying feasible metabolic  
260 routes in *Mycobacterium smegmatis* and possible alterations under diverse nutrient  
261 conditions. *BMC Microbiol* 14:276. 10.1186/s12866-014-0276-5
- 262 Bannantine JP, Bayles DO, Robbe-Austerman S, Burrell AM, and Stabel JR. 2014. Draft  
263 Genome Sequence of a *Mycobacterium avium* Complex Isolate from a Broadbill Bird.  
264 *Genome Announc* 2. 10.1128/genomeA.01268-13
- 265 Bochner BR. 2003. New technologies to assess genotype-phenotype relationships. *Nat Rev Genet*  
266 4:309-314. 10.1038/nrg1046
- 267 Bochner BR. 2009. Global phenotypic characterization of bacteria. *FEMS Microbiol Rev* 33:191-  
268 205. 10.1111/j.1574-6976.2008.00149.x
- 269 Bochner BR, Gadzinski P, and Panomitros E. 2001. Phenotype microarrays for high-throughput  
270 phenotypic testing and assay of gene function. *Genome Res* 11:1246-1255.  
271 10.1101/gr.186501
- 272 Bochner BR, Giovannetti L, and Viti C. 2008. Important discoveries from analysing bacterial  
273 phenotypes. *Mol Microbiol* 70:274-280. 10.1111/j.1365-2958.2008.06383.x
- 274 Borglin S, Joyner D, DeAngelis KM, Khudyakov J, D'Haeseleer P, Joachimiak MP, and Hazen  
275 T. 2012. Application of phenotypic microarrays to environmental microbiology. *Curr*  
276 *Opin Biotechnol* 23:41-48. 10.1016/j.copbio.2011.12.006
- 277 Chen JW, Scaria J, and Chang YF. 2012. Phenotypic and transcriptomic response of auxotrophic  
278 *Mycobacterium avium* subsp. *paratuberculosis* leuD mutant under environmental stress.  
279 *PLoS One* 7:e37884. 10.1371/journal.pone.0037884
- 280 de Sarrau B, Clavel T, Clerte C, Carlin F, Ginies C, and Nguyen-The C. 2012. Influence of  
281 anaerobiosis and low temperature on *Bacillus cereus* growth, metabolism, and membrane  
282 properties. *Appl Environ Microbiol* 78:1715-1723. 10.1128/AEM.06410-11
- 283 de Sarrau B, Clavel T, Zwickel N, Despres J, Dupont S, Beney L, Tourdot-Marechal R, and  
284 Nguyen-The C. 2013. Unsaturated fatty acids from food and in the growth medium  
285 improve growth of *Bacillus cereus* under cold and anaerobic conditions. *Food Microbiol*  
286 36:113-122. 10.1016/j.fm.2013.04.008
- 287 Despierres L, Cohen-Bacrie S, Richet H, and Drancourt M. 2012. Diversity of *Mycobacterium*  
288 *avium* subsp. *hominissuis* mycobacteria causing lymphadenitis, France. *Eur J Clin*  
289 *Microbiol Infect Dis* 31:1373-1379. 10.1007/s10096-011-1452-2
- 290 Diomande SE, Nguyen-The C, Guinebretiere MH, Broussolle V, and Brillard J. 2015. Role of  
291 fatty acids in *Bacillus* environmental adaptation. *Front Microbiol* 6:813.  
292 10.3389/fmicb.2015.00813
- 293 Falkinham JO, 3rd. 2013. Ecology of nontuberculous mycobacteria--where do human infections  
294 come from? *Semin Respir Crit Care Med* 34:95-102. 10.1055/s-0033-1333568

- 295 Gupta KR, Kasetty S, and Chatterji D. 2015. Novel functions of (p)ppGpp and Cyclic di-GMP in  
296 mycobacterial physiology revealed by phenotype microarray analysis of wild-type and  
297 isogenic strains of *Mycobacterium smegmatis*. *Appl Environ Microbiol* 81:2571-2578.  
298 10.1128/AEM.03999-14
- 299 Hayashi D, Takii T, Mukai T, Makino M, Yasuda E, Horita Y, Yamamoto R, Fujiwara A, Kanai  
300 K, Kondo M, Kawarazaki A, Yano I, Yamamoto S, and Onozaki K. 2010. Biochemical  
301 characteristics among *Mycobacterium bovis* BCG substrains. *FEMS Microbiol Lett*  
302 306:103-109. 10.1111/j.1574-6968.2010.01947.x
- 303 Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, Beylis N, Boeree MJ,  
304 Cacho J, Chihota V, Chimara E, Churchyard G, Cias R, Daza R, Daley CL, Dekhuijzen  
305 PN, Domingo D, Drobniowski F, Esteban J, Fauville-Dufaux M, Folkvardsen DB,  
306 Gibbons N, Gomez-Mampaso E, Gonzalez R, Hoffmann H, Hsueh PR, Indra A, Jagielski  
307 T, Jamieson F, Jankovic M, Jong E, Keane J, Koh WJ, Lange B, Leao S, Macedo R,  
308 Mannsaker T, Marras TK, Maugein J, Milburn HJ, Mlinko T, Morcillo N, Morimoto K,  
309 Papaventsis D, Palenque E, Paez-Pena M, Piersimoni C, Polanova M, Rastogi N, Richter  
310 E, Ruiz-Serrano MJ, Silva A, da Silva MP, Simsek H, van Soolingen D, Szabo N,  
311 Thomson R, Tortola Fernandez T, Tortoli E, Totten SE, Tyrrell G, Vasankari T, Villar M,  
312 Walkiewicz R, Winthrop KL, Wagner D, and Nontuberculous Mycobacteria Network  
313 European Trials G. 2013. The geographic diversity of nontuberculous mycobacteria  
314 isolated from pulmonary samples: an NTM-NET collaborative study. *Eur Respir J*  
315 42:1604-1613. 10.1183/09031936.00149212
- 316 Johnson DA, Tetu SG, Phillippy K, Chen J, Ren Q, and Paulsen IT. 2008. High-throughput  
317 phenotypic characterization of *Pseudomonas aeruginosa* membrane transport genes. *PLoS*  
318 *Genet* 4:e1000211. 10.1371/journal.pgen.1000211
- 319 Kanehisa M, and Goto S. 2000. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic*  
320 *Acids Res* 28:27-30.
- 321 Kanehisa M, Sato Y, Kawashima M, Furumichi M, and Tanabe M. 2016. KEGG as a reference  
322 resource for gene and protein annotation. *Nucleic Acids Res* 44:D457-462.  
323 10.1093/nar/gkv1070
- 324 Kearsse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, Cooper A,  
325 Markowitz S, Duran C, Thierer T, Ashton B, Meintjes P, and Drummond A. 2012.  
326 Geneious Basic: an integrated and extendable desktop software platform for the  
327 organization and analysis of sequence data. *Bioinformatics* 28:1647-1649.  
328 10.1093/bioinformatics/bts199
- 329 Khatri B, Fielder M, Jones G, Newell W, Abu-Oun M, and Wheeler PR. 2013. High throughput  
330 phenotypic analysis of *Mycobacterium tuberculosis* and *Mycobacterium bovis* strains'  
331 metabolism using biologic phenotype microarrays. *PLoS One* 8:e52673.  
332 10.1371/journal.pone.0052673
- 333 Kim BJ, Choi BS, Lim JS, Choi IY, Lee JH, Chun J, Kook YH, and Kim BJ. 2012. Complete  
334 genome sequence of *Mycobacterium intracellulare* strain ATCC 13950(T). *J Bacteriol*  
335 194:2750. 10.1128/JB.00295-12
- 336 Lahiri A, Kneisel J, Kloster I, Kamal E, and Lewin A. 2014. Abundance of *Mycobacterium*  
337 *avium* ssp. *hominissuis* in soil and dust in Germany - implications for the infection route.  
338 *Lett Appl Microbiol* 59:65-70. 10.1111/lam.12243

- 339 Lewin A, Freytag B, Meister B, Sharbati-Tehrani S, Schafer H, and Appel B. 2003. Use of a  
340 quantitative TaqMan-PCR for the fast quantification of mycobacteria in broth culture,  
341 eukaryotic cell culture and tissue. *J Vet Med B Infect Dis Vet Public Health* 50:505-509.
- 342 Li L, Wong HC, Nong W, Cheung MK, Law PT, Kam KM, and Kwan HS. 2014. Comparative  
343 genomic analysis of clinical and environmental strains provides insight into the  
344 pathogenicity and evolution of *Vibrio parahaemolyticus*. *BMC Genomics* 15:1135.  
345 10.1186/1471-2164-15-1135
- 346 Lofthouse EK, Wheeler PR, Beste DJ, Khatri BL, Wu H, Mendum TA, Kierzek AM, and  
347 McFadden J. 2013. Systems-based approaches to probing metabolic variation within the  
348 *Mycobacterium tuberculosis* complex. *PLoS One* 8:e75913.  
349 10.1371/journal.pone.0075913
- 350 Mackie AM, Hassan KA, Paulsen IT, and Tetu SG. 2014. Biolog Phenotype Microarrays for  
351 phenotypic characterization of microbial cells. *Methods Mol Biol* 1096:123-130.  
352 10.1007/978-1-62703-712-9\_10
- 353 Mishra MN, and Daniels L. 2013. Characterization of the MSMEG\_2631 gene (mmp) encoding  
354 a multidrug and toxic compound extrusion (MATE) family protein in *Mycobacterium*  
355 *smegmatis* and exploration of its polyspecific nature using biolog phenotype microarray.  
356 *J Bacteriol* 195:1610-1621. 10.1128/JB.01724-12
- 357 Nai C, Wong HY, Pannenbecker A, Broughton WJ, Benoit I, de Vries RP, Gueidan C, and  
358 Gorbushina AA. 2013. Nutritional physiology of a rock-inhabiting, model microcolonial  
359 fungus from an ancestral lineage of the Chaetothyriales (Ascomycetes). *Fungal Genet*  
360 *Biol* 56:54-66. 10.1016/j.fgb.2013.04.001
- 361 Nelson, D., Michael M. Cox (2004) *Lehninger Principles of Biochemistry fourth edition.* : W. H.  
362 Freeman.
- 363 Omsland A, Cockrell DC, Howe D, Fischer ER, Virtaneva K, Sturdevant DE, Porcella SF, and  
364 Heinzen RA. 2009. Host cell-free growth of the Q fever bacterium *Coxiella burnetii*.  
365 *Proc Natl Acad Sci U S A* 106:4430-4434. 10.1073/pnas.0812074106
- 366 Patel RK, and Jain M. 2012. NGS QC Toolkit: a toolkit for quality control of next generation  
367 sequencing data. *PLoS One* 7:e30619. 10.1371/journal.pone.0030619
- 368 Plata G, Henry CS, and Vitkup D. 2015. Long-term phenotypic evolution of bacteria. *Nature*  
369 517:369-372. 10.1038/nature13827
- 370 Rindi L, and Garzelli C. 2014. Genetic diversity and phylogeny of *Mycobacterium avium*. *Infect*  
371 *Genet Evol* 21:375-383. 10.1016/j.meegid.2013.12.007
- 372 Stamatakis A. 2014. RAxML version 8: a tool for phylogenetic analysis and post-analysis of  
373 large phylogenies. *Bioinformatics* 30:1312-1313. 10.1093/bioinformatics/btu033
- 374 Tohsato Y, and Mori H. 2008. Phenotype profiling of single gene deletion mutants of *E. coli*  
375 using Biolog technology. *Genome Inform* 21:42-52.
- 376 Tortoli E. 2014. Microbiological features and clinical relevance of new species of the genus  
377 *Mycobacterium*. *Clin Microbiol Rev* 27:727-752. 10.1128/CMR.00035-14
- 378 Uchiya K, Takahashi H, Yagi T, Moriyama M, Inagaki T, Ichikawa K, Nakagawa T, Nikai T,  
379 and Ogawa K. 2013. Comparative genome analysis of *Mycobacterium avium* revealed  
380 genetic diversity in strains that cause pulmonary and disseminated disease. *PLoS One*  
381 8:e71831. 10.1371/journal.pone.0071831
- 382 Vaas LA, Sikorski J, Hofner B, Fiebig A, Buddruhs N, Klenk HP, and Goker M. 2013. opm: an  
383 R package for analysing OmniLog(R) phenotype microarray data. *Bioinformatics*  
384 29:1823-1824. 10.1093/bioinformatics/btt291

- 385 Vandal OH, Nathan CF, and Ehrt S. 2009. Acid resistance in *Mycobacterium tuberculosis*. *J*  
386 *Bacteriol* 191:4714-4721. 10.1128/JB.00305-09
- 387 Vives-Florez M, and Garnica D. 2006. Comparison of virulence between clinical and  
388 environmental *Pseudomonas aeruginosa* isolates. *Int Microbiol* 9:247-252.
- 389 von Mentzer A, Connor TR, Wieler LH, Semmler T, Iguchi A, Thomson NR, Rasko DA, Joffre  
390 E, Corander J, Pickard D, Wiklund G, Svennerholm AM, Sjoling A, and Dougan G.  
391 2014. Identification of enterotoxigenic *Escherichia coli* (ETEC) clades with long-term  
392 global distribution. *Nat Genet* 46:1321-1326. 10.1038/ng.3145
- 393 Wang C, Mahrous EA, Lee RE, Vestling MM, and Takayama K. 2011. Novel Polyoxyethylene-  
394 Containing Glycolipids Are Synthesized in *Corynebacterium matruchotii* and  
395 *Mycobacterium smegmatis* Cultured in the Presence of Tween 80. *J Lipids* 2011:676535.  
396 10.1155/2011/676535
- 397 Wynne JW, Seemann T, Bulach DM, Coutts SA, Talaat AM, and Michalski WP. 2010.  
398 Resequencing the *Mycobacterium avium* subsp. *paratuberculosis* K10 genome: improved  
399 annotation and revised genome sequence. *J Bacteriol* 192:6319-6320. 10.1128/JB.00972-  
400 10
- 401

**Table 1** (on next page)

Characteristics of the ten MAH isolates analyzed in this study

1 **Table 1** Characteristics of the ten MAH isolates analyzed in this study.

MAH Isolate name	Year of isolation	Source	Provider or reference	Accession of whole genome sequence
P-10091-06	2006	Clinical - Child with lymphadenitis	NRC for Mycobacteria, Borstel, Germany	LNAV00000000
2721	2004	Clinical - Child with lymphadenitis	NRC for Mycobacteria, Borstel, Germany	AWXJ00000000
P-9-13	2013	Clinical - Adult pulmonary infection	Charité Hospital, Berlin, Germany	LNBB00000000
104	1983	Clinical - Adult pulmonary infection	Reference strain, USA	CP000479
TH135	2013	Clinical - Adult pulmonary infection	Reference strain, Japan	AP012555
E-128	2010	Environmental - Soil	Friedrich Löffler Institute, Jena, Germany	LVCS00000000
E-96-2	2010	Environmental - Soil	This study	LMVW00000000
E- 82-7	2010	Environmental - Dust	This study	LNAF00000000
27-1	2010	Environmental - Dust	This study	AWXK00000000
E-2514	na	Environmental - Water	University of Düsseldorf, Germany	LNBK00000000

2 MAH: *Mycobacterium avium* subsp. *hominissuis*; NRC: National reference center; na: not available

3

**Table 2** (on next page)

Additives used for each PM plates

As additive are usually provided nutrient that are absent to the PM minimal media, but present in a standard MAH growth conditions. We used additives to make a complete minimal medium but omitted anything that could act as a source of the substrates of interest (for example, we did not include nitrate additives in the nitrogen source plates).

- 1 **Table 2** Additives used for each PM plates. As additive are usually provided nutrient that are absent to the PM minimal media, but present in a  
 2 standard MAH growth conditions. We used additives to make a complete minimal medium but omitted anything that could act as a source of the  
 3 substrates of interest (for example, we did not include nitrate additives in the nitrogen source plates).

	<b>Additive a</b>	<b>Additive b</b>
<b>PM plate usage</b>	<b>PM1, PM2, PM4</b>	<b>PM3</b>
<b>Ingredients</b>	24mM MgCl <sub>2</sub> 12mM CaCl <sub>2</sub> 0,0012% ZnSO <sub>4</sub> 0,06% ferric ammonium citrate 1,2% NH <sub>4</sub> Cl 0,01% tween 80	24mM MgCl <sub>2</sub> 12mM CaCl <sub>2</sub> 0,0012% ZnSO <sub>4</sub> 0,01% tween 80

4

**Table 3** (on next page)

The 20 substrates differentiating the ten MAH isolates analyzed in this study.

1 **Table 3** The 20 substrates differentiating the ten MAH isolates analyzed in this study.

PM Plate	Substrate and well number	Pathway involved	Reference
PM1 Carbon	Acetic acid – C08	Pyruvate metabolism	(Baloni <i>et al.</i> 2014; Nai <i>et al.</i> 2013)
	Acetoacetic acid – G07	Pyruvate metabolism	(Baloni <i>et al.</i> 2014; Nai <i>et al.</i> 2013)
	Methyl pyruvate – G10	Pyruvate metabolism	(Baloni <i>et al.</i> 2014; Nai <i>et al.</i> 2013)
	Mono-methyl Succinate – G09	Tricarboxylic acid cycle	(Baloni <i>et al.</i> 2014; Nai <i>et al.</i> 2013)
	Propionic acid – F07	Propanoate metabolism, Nicotinate and nicotinamide metabolism, Degradation of aromatic compounds	(Baloni, <i>et al.</i> 2014; Kanehisa and Goto 2000; Kanehisa <i>et al.</i> 2016; Nai <i>et al.</i> 2013)
	D-psicose – H05	Glycolysis and branches	(Baloni <i>et al.</i> 2014; Nai <i>et al.</i> 2013)
	Pyruvic acid – H08 Tween 80 – E05	Pyruvate metabolism Fatty acid metabolism	(Baloni <i>et al.</i> 2014; Nai <i>et al.</i> 2013) (Baloni <i>et al.</i> 2014; Nai <i>et al.</i> 2013)
PM2 Carbon	L-alaninamide – G02	Amino acid metabolism	(Nai <i>et al.</i> 2013)
	Butyric acid – D12	Butanoate metabolism	(Baloni, <i>et al.</i> 2014; Kanehisa and Goto 2000; Kanehisa <i>et al.</i> 2016; Nai <i>et al.</i> 2013)
	Caproic acid – E02	Carboxylic acid metabolism	(Nai <i>et al.</i> 2013)
	L-histidine – G06	Amino acid metabolism	(Nai <i>et al.</i> 2013)
	$\gamma$ -hydroxy-butyric acid – E09	Succinate metabolism	(Breitkreuz <i>et al.</i> 2003; Nai <i>et al.</i> 2013)
	$\beta$ -methyl-D-galactoside – C07 Sebacic acid – F08	Galactose Metabolism Carboxylic acid metabolism	(Nai <i>et al.</i> 2013) (Nai <i>et al.</i> 2013)
PM3 Nitrogen	D,L- $\alpha$ -amino-caprylic acid – G10	Amino acid metabolism	(Baloni <i>et al.</i> 2014)
	L-cysteine – A11	Amino acid metabolism	(Baloni <i>et al.</i> 2014)
	D-galactosamine – E09	Amino-sugar pathway	(Baloni <i>et al.</i> 2014)
PM4 Phosphorous and sulphur	Carbamyl phosphate – B05	Urea cycle and Pyrimidine synthesis	(Nelson 2004)
	Sodium pyrophosphate – A03	Phosphoric acid synthesis	(Nelson 2004)

2

3

4

5

**Figure 1**(on next page)

Heatmap showing the 20 substrates that were differently metabolized by the ten MAH isolates analyzed in this study.

The color key scale for each substrate is based on dye reduction quantified by Omnilog units. A yellow color indicates strong positive substrate metabolization, a green color moderate metabolization and a blue color indicates no substrate metabolization. Regarding the MAH isolates, environmental isolates are marked in orange, while clinical isolates are marked in blue.




Figure 1.

**Figure 2**(on next page)

Clustering of the 10 MAH isolates.

The tree was generated using RAxML 8.1. The alignment comprised 1,658 genes constituting the maximum common genome of our ten MAH isolates. Two reference strains were also included (MAH 104 and MAH TH135). The genome sequence of *M. avium* subsp. *paratuberculosis* K10 (Accession Number: AE016958) was used as outgroup. Isolate origin is also represented by blue for clinical origin and orange for environmental origin. The percentage of trees in which the associated taxa clustered together is shown adjacent to the branches.




Figure 2.